FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
IONSIonis' Tryngolza receives FDA approval for familial chylomicronemia syndrome, showing significant triglyceride reduction and fewer pancreatitis events.
Needham Maintains Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
IONSIonis Pharmaceuticals' TRYNGOLZA (olezarsen) Becomes First FDA-Approved Treatment For Adults with Familial Chylomicronemia Syndrome
IONSTrading Halt: Halt status updated at 6:55:00 PM ET: Quotation Resumption: News and Resumption Times
IONSTrading Halt: Halted at 4:28:30 p.m. ET - Trading Halt: Halt News Pending
IONSPiper Sandler Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $62
IONSIonis Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results and announced the pivotal Phase 3 study design following alignment with the FDA on ION582 for Angelman syndrome.
IONSIonis Pharmaceuticals Q3 2024 Adj EPS $(0.72) Beats $(1.16) Estimate, Sales $134.00M Beat $130.13M Estimate
IONSIonis Pharmaceuticals Announced The Pivotal Phase 3 Study Design Following Alignment With The FDA On ION582 For Angelman Syndrome
IONSIonis Announces FDA Acceptance Of New Drug Application For Donidalorsen, Aiming For First-In-Class RNA-Targeted Treatment For Hereditary Angioedema; PDUFA Date Set For August 21, 2025
IONSIonis Pharmaceuticals Announced Topline Data From HALOS Phase 1/2A Open-label Study Of ION582 In Angelman Syndrome, ION582 Was Safe And Well Tolerated In The Study And Showed Encouraging And Consistent Benefits
IONSThere's 'Outsized' Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%
IONSAnalyst Ratings for Ionis Pharmaceuticals
IONSOver the past 3 months, 6 analysts have published their opinion on Ionis Pharmaceuticals (NASDAQ:IONS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Morgan Stanley Upgrades Ionis Pharmaceuticals to Overweight, Raises Price Target to $57
IONSRecap: Ionis Pharmaceuticals Q1 Earnings
IONSIonis Pharmaceuticals (NASDAQ:IONS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
UPDATE: Ionis Pharmaceuticals Q1 Adj. EPS $(0.27)
IONSIonis Pharmaceuticals Q1 Adj. EPS $(0.27) Beats $(0.71) Estimate, Sales $142.00M Beat $125.21M Estimate
IONS